Immune Based Articles & Analysis: Older
25 news found
The enzyme DGKzeta is a lipid kinase that can down-modulate T-cell activation by catalyzing the conversion of diacylglycerol to phosphatidic acid, thus acting as a ligand-independent, intracellular immune checkpoint. An inhibition of DGKzeta has been demonstrated to enhance T-cell priming against suboptimal tumor antigens and has the potential to overcome multiple ...
ByBayer AG
A novel RNA-based IL-2 treatment response classifier was developed as part of the study in patients with renal cell carcinoma Durham, NC, August 23, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced its new publication in Cancer Research Communications that compares the immunogenomic ...
Statistically significant peak immunity was reached after 6 months of GP2 treatment, as measured in both the Dimer Binding Assay and the DTH skin test. HER2/neu 3+ population immune response was similar to the HER2/neu 1-2+ population immune response, suggesting the potential to treat the HER2/neu 1-2+ population (including triple negative breast ...
Statistically significant peak immunity was reached after 6 months of GP2 treatment, as measured in both the Dimer Binding Assay and the DTH skin test. HER2/neu 3+ population immune response was similar to the HER2/neu 1-2+ population immune response, suggesting the potential to treat the HER2/neu 1-2+ population (including triple negative breast ...
MiXCR 4.0 is enhanced software for analysis of genomics data and building a comprehensive picture of the immune response. Leading pharmaceutical research and development (R&D) teams can leverage MiXCR 4.0 for drug discovery pipelines, and for analyzing DNA sequencing data unraveling genomic information about antibodies, T-cell, and B-cell receptors. ...
Liaison Memed Bv is an immune system based protein signature test for distinguishing between bacterial and viral infections The test was developed following the licensing agreement signed with Memed as announced in September 2020 The new test is available on the Liaison Xl platforms in countries that accept CE mark and U.S. food and drug administration ...
ByMeMed
Oral and poster presentations highlight robust and high-quality immune responses following administration of novel arenaviral therapeutic vaccines in preclinical setting Alternating 2-vector therapy induces greater immune response than single-vector therapy in preclinical setting and translates into significant reduction of viral load HOOKIPA Pharma Inc. ...
We are planning to study the peak immunity of GP2 and how to assess when to administer booster injections. ...
Durham, NC, May 10, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today an upcoming presentation of initial results from the GARNER (Genomic Analysis of high-Risk Non-muscle invasive bladder cancer) real-world study at the 2022 American Urological Association (AUA) Annual Meeting, which is being ...
Oral cavity HNSCC patients with lymph node-negative disease, who are typically treated with surgical resection without additional radiation and/or chemotherapy, were identified as mesenchymal or non-mesenchymal based upon the novel RNA-based signature. For the nearly one-quarter who were mesenchymal, survival was 2.4-fold worse compared to the remaining ...
Statistically significant peak immunity was reached after 6 months of GP2 treatment, as measured in both the Dimer Binding Assay and the DTH skin test. HER2/neu 3+ population immune response was similar to the HER2/neu 1-2+ population immune response, suggesting the potential to treat the HER2/neu 1-2+ population (including triple negative breast ...
Statistically significant peak immunity was reached after 6 months of GP2 treatment, as measured in both the Dimer Binding Assay and the DTH skin test. HER2/neu 3+ population immune response was similar to the HER2/neu 1-2+ population immune response, suggesting the potential to treat the HER2/neu 1-2+ population (including triple negative breast ...
(Prellis), a Bay Area biotechnology company, announced today that it has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing Prellis Biologics’ first-in-class externalized human immune system (EXIS) based on human lymph node organoids (LNO). The collaboration leverages Prellis’ EXIS ...
The Piedmont Study paired highly curated real-world clinical and demographic data with bulk tumor RNA transcriptome analysis from patients with NSCLC, which was analyzed using GeneCentric’s RNA-based Tumor and Immune Micro-Environment (rT(I)ME) Explorer platform. ...
Orally available Alphataxin, is the first and only drug in development to increase formation of CD4+ helper T cells. Immune checkpoint inhibitor therapy, the vanguard of cancer therapy, promotes the ability of CD8+ T cells to kill tumor cells. ...
Statistically significant peak immunity was reached after 6 months of GP2 treatment, as measured in both the Dimer Binding Assay and the DTH skin test. HER2/neu 3+ population immune response was similar to the HER2/neu 1-2+ population immune response, suggesting the potential to treat the HER2/neu 1-2+ population (including triple negative breast ...
About the rT(I)ME Explorer Platform GeneCentric’s broad pipeline of novel predictive response signatures has been built over the past decade using its proprietary RNA-based Tumor and Immune Micro-Environment (rT(I)ME) Explorer bioinformatics platform. These RNA-based response signatures allow for improved patient selection for new and ...
This expanded collaboration will be instrumental in helping us commercialize our novel, RNA-based diagnostics.” RNA-based gene signatures provide deeper insights of the tumor and immune micro-environment when compared to traditional DNA testing. ...
Expands existing CDK7 drug discovery partnership with additional CDK targeting drugs Oxford & Shanghai – July 21st, 2021 – Exscientia, an AI-driven pharmatech company with a mission to revolutionise how drugs are discovered, and GT Apeiron Therapeutics (Apeiron), a Shanghai based company focused on novel oncology drugs, announced today a strategic research and ...
The second manuscript has been published in “Vaccine” and provides important data validating the potential of V-306 to be administered ‘epicutaneously’ via skin patch delivery, as a method to boost protective immunity to RSV following initial intramuscular injection. Following administration of V-306, the immune response is characterized ...